$AKTX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Akari Therapeutics Plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Akari Therapeutics Plc. Get notifications about new insider transactions in Akari Therapeutics Plc for free.
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 30 2016 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Jun 30 2016 | AKTX | Akari Therapeutics ... | Byrne David | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Jun 30 2016 | AKTX | Akari Therapeutics ... | Hill James | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Jun 30 2016 | AKTX | Akari Therapeutics ... | Ungar Stuart | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Jun 30 2016 | AKTX | Akari Therapeutics ... | Williams Donald Allen | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Jun 30 2016 | AKTX | Akari Therapeutics ... | Williams Donald Allen | Director | Option Exercise | A | 0.15 | 1,300,000 | 189,020 | 1,300,000 | |
Apr 26 2016 | AKTX | Akari Therapeutics ... | Byrne David | Director | Option Exercise | A | 17.96 | 1,300,000 | 23,348,000 | 1,300,000 | |
Mar 25 2016 | AKTX | Akari Therapeutics ... | SHAW ROBERT M | General Counsel and ... | Option Exercise | A | 14.10 | 1,800,000 | 25,380,000 | 1,800,000 | |
Nov 25 2015 | AKTX | Akari Therapeutics ... | Ungar Stuart | Director | Option Exercise | A | 0.19 | 1,088,722 | 208,708 | 1,088,722 | |
Nov 25 2015 | AKTX | Akari Therapeutics ... | Hill James | Director | Option Exercise | A | 0.19 | 1,068,722 | 204,874 | 1,068,722 | |
Nov 25 2015 | AKTX | Akari Therapeutics ... | Shaw Allan | Director | Option Exercise | A | 0.19 | 1,068,722 | 204,874 | 1,068,722 | |
Nov 25 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | A | 0.19 | 1,028,722 | 197,206 | 1,028,722 | |
Sep 23 2015 | AKTX | Akari Therapeutics ... | Shaw Allan | Director | Option Exercise | A | 0.32 | 186,278 | 60,000 | 186,278 | |
Sep 23 2015 | AKTX | Akari Therapeutics ... | Shaw Allan | Director | Option Exercise | A | 0.32 | 45,000 | 14,495 | 45,000 | |
Sep 23 2015 | AKTX | Akari Therapeutics ... | Hill James | Director | Option Exercise | A | 0.32 | 231,278 | 74,495 | 231,278 | |
Sep 23 2015 | AKTX | Akari Therapeutics ... | Richardson Clive | COO | Option Exercise | A | 0.32 | 16,271,850 | 5,241,163 | 16,271,850 | |
Sep 23 2015 | AKTX | Akari Therapeutics ... | Ungar Stuart | Director | Option Exercise | A | 0.32 | 211,278 | 68,053 | 211,278 | |
Sep 22 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | A | 0.32 | 186,278 | 60,000 | 186,278 | |
Sep 22 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | A | 0.32 | 85,000 | 27,379 | 85,000 | |
Sep 22 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Buy | P | 0.19 | 1,055,600 | 200,036 | 1,055,600 | 0 to 1.1 M |
Sep 22 2015 | AKTX | Akari Therapeutics ... | Elefant Dov | Chief Financial Off ... | Option Exercise | A | 0.32 | 4,067,963 | 1,310,291 | 4,067,963 | |
Sep 22 2015 | AKTX | Akari Therapeutics ... | Roshwalb Gur | Chief Executive Off ... | Option Exercise | A | 0.32 | 32,543,700 | 10,482,326 | 32,543,700 | |
Jan 12 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | X | 0.02 | 152,000 | 2,326 | 0 | |
Jan 12 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Option Exercise | X | 0.02 | 50,700 | 847 | 0 | |
Jan 12 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Buy | X | 0.02 | 152,000 | 2,326 | 152,000 | 0 to 152 K |
Jan 12 2015 | AKTX | Akari Therapeutics ... | Cohen Mark S | Director | Buy | X | 0.02 | 50,700 | 847 | 50,700 | 0 to 50.7 K |
Apr 17 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.00 | 17,100 | 85,500 | 778,030 | 760.9 K to 778 K (+2.25 %) |
Apr 17 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.21 | 3,000 | 15,630 | 760,930 | 757.9 K to 760.9 K (+0.40 %) |
Apr 11 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.15 | 100 | 515 | 757,930 | 757.8 K to 757.9 K (+0.01 %) |
Apr 11 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.25 | 1,400 | 7,350 | 757,830 | 756.4 K to 757.8 K (+0.19 %) |
Apr 11 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.51 | 1,075 | 5,923 | 756,430 | 755.4 K to 756.4 K (+0.14 %) |
Apr 08 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.36 | 35,500 | 190,280 | 755,355 | 719.9 K to 755.4 K (+4.93 %) |
Apr 08 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.00 | 3,754 | 22,524 | 719,855 | 716.1 K to 719.9 K (+0.52 %) |
Apr 08 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 5.64 | 16,900 | 95,316 | 716,101 | 699.2 K to 716.1 K (+2.42 %) |
Apr 08 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.08 | 11,250 | 68,400 | 699,201 | 688 K to 699.2 K (+1.64 %) |
Apr 08 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.00 | 1,000 | 6,000 | 687,951 | 687 K to 688 K (+0.15 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.15 | 2,500 | 15,375 | 686,951 | 684.5 K to 687 K (+0.37 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.12 | 7,496 | 45,876 | 684,451 | 677 K to 684.5 K (+1.11 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.08 | 7,375 | 44,840 | 676,955 | 669.6 K to 677 K (+1.10 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.18 | 500 | 3,090 | 669,580 | 669.1 K to 669.6 K (+0.07 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.65 | 2,400 | 15,960 | 661,144 | 658.7 K to 661.1 K (+0.36 %) |
Apr 02 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.35 | 7,936 | 50,394 | 669,080 | 661.1 K to 669.1 K (+1.20 %) |
Mar 27 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.61 | 1,700 | 11,237 | 658,744 | 657 K to 658.7 K (+0.26 %) |
Mar 27 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.65 | 13,300 | 88,445 | 657,044 | 643.7 K to 657 K (+2.07 %) |
Mar 27 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.86 | 900 | 6,174 | 643,744 | 642.8 K to 643.7 K (+0.14 %) |
Mar 27 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.90 | 303 | 2,091 | 642,844 | 642.5 K to 642.8 K (+0.05 %) |
Mar 24 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.71 | 2,400 | 16,104 | 642,541 | 640.1 K to 642.5 K (+0.37 %) |
Mar 24 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.83 | 4,900 | 33,467 | 640,141 | 635.2 K to 640.1 K (+0.77 %) |
Mar 24 2014 | AKTX | Akari Therapeutics ... | SABBY MANAGEMENT, LLC | 10% Owner | Buy | P | 6.90 | 3,800 | 26,220 | 635,241 | 631.4 K to 635.2 K (+0.60 %) |
Page: 1